Endometrial Cancer Trial, Recruiting NCT05610501 Sponsor: Universitaire Ziekenhuizen KU Leuven Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT05610501
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The tumor or lesion being biopsied must be safely reachable by a biopsy needle, with no organs or blood vessels in the way, and must have a solid portion (not purely fluid-filled cysts). For biopsies approached through the vagina, severe vaginal narrowing must not be present.
  • People with a gynecological tumor who are already being considered for another clinical trial that requires a tissue sample for research purposes.
  • People with a suspected new, widespread gynecological tumor who need a tissue sample confirmed by a laboratory before treatment can begin, and who are not suitable for major surgery either because of other health conditions or because the disease has spread too extensively.
  • People with a suspected new, widespread non-gynecological tumor (or its spread) where a tissue sample is needed to confirm the diagnosis.
  • People with a possible return of a gynecological cancer (such as cervical, uterine, or ovarian cancer) where laboratory confirmation of the recurrence is needed before surgery or other treatment can begin.
  • People with a possible return of a non-gynecological cancer where laboratory confirmation is needed before treatment can begin.
  • People with a single tumour of unknown type located in the vaginal wall, the tissue around the uterus, the space behind the abdominal lining, or the uterine wall, where a biopsy can be taken without spillage into the abdominal cavity.

Who may not be able to join:

  • People under 18 years of age.
  • People with a blood-clotting problem or who are taking blood-thinning medication that would make a biopsy unsafe, even with adjustments to their medication.
  • People with an active infection in the vagina or pelvis.
  • People whose general health is too poor to be considered for any specific cancer treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +3216344202

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2021
Est. completion
30 April 2025

Where this trial is recruiting

🇧🇪 Belgium 🇨🇿 Czechia 🇮🇹 Italy 🇸🇪 Sweden

Primary endpoints

Safety; Tissue yield

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov